Basal Insulin Analogues Similar for Glucose Lowering

Share this content:
Basal Insulin Analogues Similar for Glucose Lowering
Basal Insulin Analogues Similar for Glucose Lowering

WEDNESDAY, July 18, 2018 (HealthDay News) -- Basal insulin analogues for type 2 diabetes mellitus (T2DM) do not substantially differ in their glucose-lowering effect, according to a review published online July 10 in the Annals of Internal Medicine.

Anastasia-Vasiliki Madenidou, M.D., from the Aristotle University of Thessaloniki in Greece, and colleagues conducted a systematic literature review to assess the comparative efficacy and safety of basal insulin analogues for adults with T2DM.

The researchers identified a total of 39 eligible trials (26,195 patients). Thrice-weekly degludec (Deg-3TW) was inferior to most other regimens for reducing glycated hemoglobin levels, according to low- to very-low-quality evidence. Detemir had a favorable weight profile versus all comparators based on high- to moderate-quality evidence. Glar-300 was associated with less weight gain than glargine, 100 U/mL (Glar-100); Deg-100; degludec, 200 U/mL (Deg-200); Deg-3TW; and LY2963016. Deg-100, Deg-200, and Glar-300 were associated with lower incidence of nocturnal hypoglycemia than detemir, Glar-100, LY2963016, and neutral protamine lispro (NPL), but the evidence was low- and very-low quality. Only NPL was associated with increased incidence of severe hypoglycemia versus Deg-100, detemir, Glar-100, and Glar-300.

"Low-quality evidence suggests that basal insulin analogues for T2DM do not substantially differ in their glucose-lowering effect," the authors write.

One author disclosed receiving personal fees from pharmaceutical companies.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »